Onco-innovations Ltd. Stock
Price
Target price
€0.98
€0.98
-2.500%
-0.025
-2.500%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Onco-innovations Ltd. Stock
We can see a decrease in the price for Onco-innovations Ltd.. Compared to yesterday it has lost -€0.025 (-2.500%).
Our community identified positive and negative aspects for Onco-innovations Ltd. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Onco-innovations Ltd. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Onco-innovations Ltd. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering
Vancouver, Canada – December 07, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) (“Onco” or the “Company”) is pleased to announce that it has
Onco-Innovations Attends University of Alberta’s 2025 Innovation Awards
Vancouver, Canada – November 25, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (Frankfurt: W1H, WKN: A3EKSZ)(OTCQB: ONNVF) ("Onco" or the "Company") is pleased to announce that it was
Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies
Vancouver, Canada – November 20, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that its